Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib-Reference-Cited by-同舟云学术

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Published:2018-09 Issue:9 Volume:8 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Ottmann Oliver,Saglio Giuseppe,Apperley Jane F.,Arthur Christopher,Bullorsky Eduardo,Charbonnier Aude,Dipersio John F.,Kantarjian Hagop,Khoury Hanna Jean,Kim Dong-Wook,Healey Diane,Strauss Lewis,Cortes Jorge E.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-018-0122-3.pdf

Reference9 articles.

1. Sasaki, K. et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2, e186–e193 (2015).

2. Ohanian, M. et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin. Lymphoma Myeloma Leuk. 14, 155–162 (2014). e1.

3. Rea, D. et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 26, 2254–2259 (2012).

4. Kantarjian, H. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113, 6322–6329 (2009).

5. Radich, J. Major progress in understanding progression in chronic myeloid leukemia. J. Exp. Med. 212, 1482 (2015).

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia-A Single-institution Retrospective Study-;Internal Medicine;2024

2. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies;Current Treatment Options in Oncology;2023-12

3. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia;Current Hematologic Malignancy Reports;2023-08-31

4. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress;American Journal of Hematology;2023-06-26

5. Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4/YAP and ROCK/MLC pathways;Journal of Natural Medicines;2023-06-22